NEW DATABASE OF POTENTIAL DRUG COMPOUNDS TO AID DESIGN OF AIDS AND CANCER TREATMENTS

27-Jul-2001

The new release includes biological activity data for all compounds tested in the National Cancer Institute (NCI)’s anti-HIV and anti-cancer screens, about 23,000 new compounds. The database is the first of its kind to include 3D conformations, which give scientists added insight in the drug design process. The structural information will enable Catalyst users to pinpoint more rapidly and accurately those compounds that bind to protein targets of interest.

Dr. Omoshile Clement, the Catalyst Product Manager at Accelrys, comments, “The new release of the Catalyst/NCI2000 database offers an unparalleled opportunity for drug discovery in an area desperate for new therapeutics. With few effective treatments available to fight diseases such as AIDS and cancer, this database will be of enormous benefit to commercial and academic researchers. I expect it to result in significant advancements in pharmacophore design of such new drugs.”

About Catalyst and the Catalyst/NCI2000 database

Catalyst is Accelrys’ leading rational drug design software. It provides a sophisticated environment for pharmacophore modeling and is used by over 130 pharmaceutical and biotech companies around the world.

The Catalyst/NCI2000 database is an important source of comprehensive knowledge of potential drug compounds for academic and commercial researchers designing, identifying, and evaluating new therapeutic candidates.

Other news from the department

Most read news

More news from our other portals

Discover the latest developments in battery technology!